Investors

IR Overview

IR Overview

Cómo funcionan nuestras células SPEAR T

IR OVERVIEW

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

 

Recent News

More >>
Date Title  
Toggle Summary Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, United Kingdom , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, United Kingdom , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American
Toggle Summary Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, United Kingdom , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, United Kingdom , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary
Toggle Summary Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”)
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”)
Toggle Summary Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, UK , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA, Pa. and OXFORD, UK , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just click here.